MetaCap

Molecular Partners AG ADR (MOLN)

NASDAQ: MOLNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

2.53-0.14 (-5.25%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MOLN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$96.80M
EPS (TTM)
-$1.68
52-week range
2.52 – 5.36
Day range
2.53 – 2.53
Volume / Avg
928 / 1.63K
Beta
—

52-week range

$2.52$5.36

MOLN stock today

Shares of Molecular Partners (MOLN) finished lower on Nov 20 at $2.53, a drop of 5.25% or $0.14 per share, versus the S&P 500's 3.70% decline. At this level, MOLN sits near the bottom of its 52-week range of $2.52 to $5.36: 52.9% below the high, set on Feb 27, 2026 and 0.2% above the low. MOLN is down 42.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 37.5%.

Molecular Partners has posted a net loss over the last twelve months (EPS of -$1.68), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Molecular Partners

Company profile

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Patrick Amstutz Ph.D.
Headquarters
Schlieren
Employees
134
IPO year
2021

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$9.99+295.64%

  • Strong buy 0
  • Buy 4
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $3.74High $16.77

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$-0.41 vs $-0.46
Surprise
+10.87%

MOLN news

All MOLN news

Molecular Partners peers

Health Care sector
MOLN peer companies
CompanyPrice% ChgMarket capCompare
IPHAInnate Pharma S.A. ADS0.8634-8.14%$96.44Mvs MOLN
VYGRVoyager Therapeutics Inc.1.53-4.97%$95.21Mvs MOLN
OTLKOutlook Therapeutics Inc.0.39-2.74%$94.94Mvs MOLN
LENZLENZ Therapeutics Inc.2.97-11.23%$93.16Mvs MOLN
ZURAZura Bio Limited Class A0.9305-2.30%$89.63Mvs MOLN
CRDLCardiol Therapeutics Inc. Class A0.8626-2.28%$110.14Mvs MOLN
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs MOLN
ARMPArmata Pharmaceuticals Inc.3.03+1.68%$112.69Mvs MOLN

Indexes, lists and sector

Molecular Partners stock FAQ

What is Molecular Partners's stock price today?

MOLN last traded at $2.53 as of Nov 20, 4:00 PM EST, down 5.25% on the day. Prices are delayed at least 15 minutes.

Who is Molecular Partners's CEO?

Dr. Patrick Amstutz Ph.D. is the chief executive officer of Molecular Partners AG ADR, which has about 134 employees.

What is the MOLN 52-week high?

The 52-week high for MOLN is $5.36 and the 52-week low is $2.52. The stock is currently 52.9% below its high.

Compare MOLN